Physician profile
Ana Gowani
NPI 1053843524
$4,498.02
in general payments reported to CMS, 2019-2025
25 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $489 · 2023: $1,027 · 2024: $1,973 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,831.16 |
| Education | $178.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $914.62 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $744.73 | 2022-2025 | |
| Janssen Biotech, INC. | $428.58 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $351.33 | 2022-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $242.18 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $208.24 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $204.76 | 2022-2025 | Lupkynis |
| Genzyme Corporation | $176.54 | 2023-2025 | |
| Ucb, INC. | $164.28 | 2022-2025 | Bimzelx, Cimzia |
| Organon LLC | $159.45 | 2023-2025 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $151.19 | 2022-2025 | Orencia |
| Pfizer INC. | $146.12 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $86.00 | 2023-2025 | Idacio |
| Glaxosmithkline, LLC. | $81.65 | 2022-2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $81.33 | 2023-2025 | Strensiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $69.86 | 2024-2025 | Tymlos |
| Sandoz INC. | $62.06 | 2023-2025 | Hyrimoz |
| Almatica Pharma LLC | $33.96 | 2024 | Teriparatide |
| Actelion Pharmaceuticals US, INC. | $31.54 | 2024 | Uptravi, Opsumit |
| Genentech USA, INC. | $30.84 | 2024-2025 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $30.79 | 2024 | Arcalyst |
| Ani Pharmaceuticals, INC. | $30.49 | 2024 | Purified Cortrophin Gel |
| Tersera Therapeutics LLC | $25.77 | 2025 | Quzyttir |
| Hikma Pharmaceuticals USA | $21.34 | 2023 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.37 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Gowani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.